Holen Sie sich die Stockscreener-App
36.26
2.60%
0.92
Handel nachbörslich:
36.26
Schlusskurs vom Vortag:
$35.34
Offen:
$34.85
24-Stunden-Volumen:
2.75M
Relative Volume:
2.57
Marktkapitalisierung:
$3.67B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-804.34M
KGV:
-4.8541
EPS:
-7.47
Netto-Cashflow:
$-531.06M
1W Leistung:
-5.74%
1M Leistung:
-22.57%
6M Leistung:
+8.43%
1J Leistung:
-4.38%
1-Tages-Spanne:
$34.46
$36.95
1-Wochen-Bereich:
$34.46
$42.13
52-Wochen-Spanne:
$26.80
$62.21
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie BHVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
36.26 | 3.67B | 0 | -804.34M | -531.06M | -9.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Geode Capital Management LLC Buys 44,174 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven (NYSE:BHVN) Stock Price Down 6.1%What's Next? - MarketBeat
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - AOL
Bernstein reiterates Outperform rating on Biohaven stock, sees strong upside potential - Investing.com Australia
Biohaven's (BHVN) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Biohaven (NYSE:BHVN) Given Buy Rating at HC Wainwright - MarketBeat
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
Biohaven (NYSE:BHVN) Shares Gap DownWhat's Next? - MarketBeat
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire
Biohaven Ltd. (NYSE:BHVN) Holdings Boosted by Barclays PLC - MarketBeat
Wellington Management Group LLP Boosts Stock Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven's SWOT analysis: neurological drug developer's stock poised for growth - Investing.com
12 Best Weight Loss Stocks to Buy According to Hedge Funds - Insider Monkey
State Street Corp Sells 393,278 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Proposed Public Offering of Common Shares - The Eastern Progress Online
Learn to Evaluate (BHVN) using the Charts - Stock Traders Daily
Y Intercept Hong Kong Ltd Acquires Shares of 26,789 Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - The Eastern Progress Online
Biohaven Ltd. (NYSE:BHVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - The Eastern Progress Online
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Rel - GuruFocus.com
Biohaven Pharma (BHVN) Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates - StreetInsider.com
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting – Company AnnouncementFT.com - Financial Times
Fmr LLC Sells 13,092 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Stifel Financial Corp Purchases 28,684 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Redmile Group LLC - MarketBeat
Point72 Asset Management L.P. Has $74.97 Million Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Biohaven shares target increased, rating held on FDA catalyst potential By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Has $31.62 Million Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Janus Henderson Group PLC Boosts Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Holocene Advisors LP Lowers Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Erste Asset Management GmbH Invests $2.62 Million in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Analysts Set Biohaven Ltd. (NYSE:BHVN) Price Target at $62.75 - MarketBeat
Trading (BHVN) With Integrated Risk Controls - Stock Traders Daily
Fred Alger Management LLC Grows Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
D.A. Davidson & CO. Makes New $1.20 Million Investment in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Intech Investment Management LLC Acquires New Stake in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Citigroup Inc. Has $5.99 Million Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Eventide Asset Management LLC - MarketBeat
Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN) - Seeking Alpha
Algert Global LLC Acquires 24,990 Shares of Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Biohaven’s Phase III SMA miss: was it the target or the trial design? - BioCentury
Biohaven's (BHVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Scholar Rock shares surge 26% as rival Biohaven misses SMA study goal - TradingPedia
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial - BioPharma-Reporter.com
Biohaven's spinal muscular atrophy drug fails to meet study goal - Reuters
Biohaven shares retains overweight rating on clinical trial By Investing.com - Investing.com South Africa
Biohaven shares retain Outperform rating as Baird highlights optimism for obesity Phase 2 trial By Investing.com - Investing.com South Africa
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study - Benzinga
Biohaven muscle drug misses goal of SMA study, but advances in obesity - BioPharma Dive
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):